DRUG · Unmapped registry intervention
Pyrotinib
Find medicine records ·
Find other trials using this name
Clinical trial
Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer
NCT05880927
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedPyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer
Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Breast Cancerverified · MONDO: breast cancer
Interventions
PyrotinibDRUG
Sponsors & collaborators
Taizhou Hospitallead sponsor
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05880927 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.